H.C. Wainwright analyst Patrick Trucchio raised the firm’s price target on Arrowhead (ARWR) to $80 from $60 and keeps a Buy rating on the ...

In preclinical studies, investigational ARO-ALK7 silenced Activin receptor-like kinase 7 (ALK7) expression in adipose tissue, which led to reduced body ...

ARWR READ THE FULL ARWR RESEARCH REPORT Business Update Collaboration Deal with Sarepta Includes $825 Million Upon Closing On November 26, 2024, Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) announced ...

On Friday, Arrowhead Pharmaceuticals Inc (ARWR) stock saw a decline, ending the day at $26.03 which represents a decrease of $-0.12 or -0.46% from the prior close of $26.15. The stock opened at $26.15 ...

Arrowhead Pharmaceuticals (NASDAQ:ARWR – Free Report) had its target price trimmed by Sanford C. Bernstein from $27.00 to $24 ...

Algert Global LLC reduced its position in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Free Report) by 8.6% in ...

Goldman has recently initiated Arrowhead Pharmaceuticals Inc (ARWR) stock to Neutral rating, as announced on June 5, 2024, according to Finviz. Earlier, on December 4, 2023, BofA Securities had ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Arrowhead Pharmaceuticals (ARWR – Research ...

U.S. stocks on Wednesday slipped, as investors digested a slight acceleration in the Federal Reserve's favorite inflation gauge. Here are some of Wednesday's biggest stock movers: Biggest stock ...

Arrowhead Pharmaceuticals' stock rallied 17% due to significant pipeline developments and strategic partnerships. Learn more ...

Strategic Sarepta partnership and FDA filing position Arrowhead for a transformative leap in RNAi therapeutics ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its 2024 fiscal year ended September 30, 2024. The Company is hosting a conference ...